Summit Therapeutics Share Discussion Threads

[barrieb] 09/8/2018 21:15

Waterloo01 - many thanks for helping with my understanding of the situation, it has certainly helped knowing that you have not lost all faith in the management!

Lets all hope that Dame Kay will be able to explain at some point (although I believe this should be a GE duty) and that her exceptional work will not be in vain. I just hope that there has not been a severe breakdown in the relationship and she is able to accept this decision with grace and understanding as it would be a bit of a blow if Sarepta or someone else took up the batten and finally cracked it on the back of all our hard work. Or do you believe Summit would be able to stop this from happening?


Many thanks & lets look forward to the progression of RDZ.

[waterloo01] 09/8/2018 19:14

Listened to the Canaccord presentation. Interesting to get more on how Discuva platform works and that more targets are to be announced. People at WHO taking notice of new targets in Gonorrhoea .$4.5m grant money already gained toward getting new target through phase 1.

Good case for why RDZ should be 1st and 2nd line. Good stewardship. Presentation of RDZ microbiome detail compelling on recurrence. Interesting Q&A on financial incentives and economic case. Barda' $62m is 'effectively free money' out of confirmed cost of $100m.


Cash at end April around current market cap.

[waterloo01] 09/8/2018 15:47

Barrie, understand your view and while it would be interesting to know why it didn't work, I suspect we'll get some papers out of Dame Kay explaining more at some point, being her lifes work. However I'm thankful that they have canned it straight away and without delay (undue haste even) and without spending any more cash. DMD was always high risk/high reward. It's very easy to keep going with a drug that is either not going anywhere or would need serious investment to see if it MIGHT. We've had experience of this before with Summit, pre Glyn, when they were firing off in all sorts of directions (tau work, Seglin that disappeared into BMS etc, and there are numerous recent/current biotechs clinging onto a vain hope that a failed drug will still work.

RDZ was the original reason I got interested in Summit all those years ago and I remain convinced that it and the newer antibiotic work, will pay dividends, although maybe not the heady days of the potential return offered by rare diseases, but still a lot more than it's current valuation.

[barrieb] 09/8/2018 15:10

chrisatrdg - him sounding enthusiastic doesn't seem to wash with me any more, just not sure if we can trust him!

For those more learned than me ref. DMD - Don't you think it is about time we had a detailed proper explanation of what went wrong with the DMD trial. As well as what is happening with their relationship with Oxford University and if they will ever resurrect this programme further down the line with improved versions or perhaps a new mechanism / technology as they have stated that utrophin modulation could still play a part DMD treatment. It just seems that we are left clutching at straws after Glynn was so excited over its apparent potential, only for a complete change of mind and apparently results, within a very short space of time. Something does just not add up here as a proper up front explanation should surely be a top priority for a supposedly trustworthy company worthy of continued and further investment.

I am sure like me many on here have lost large amounts of money on our investment in SUMM and I just feel we have not been treated with the greatest of respect. However, as we all know longevity of the human race may depend on the development of novel antibiotics, so I have decided to at lease double up in terms of original quantity of shares held, with the initial intention of getting my money back and then reviewing what the prospects are for holding longer term, although this obviously depends whether I am still around then to make that call!!!

Many thanks for the expertise freely given by contributors it really has been a very interesting board to read, especially before the DMD shock!

Good luck to all those that are brave enough to stick with it

[chrisatrdg] 09/8/2018 13:31

Todays presentation

Listened with interest today & Glyn once again sounding enthusiastic about the various pipe lines but not sure we learnt anything new.

[kirk 6] 08/8/2018 09:44

This will do a farn .... just a matter of waiting

[someuwin] 07/8/2018 14:22

No online buy quote for just £2k.

[kirk 6] 07/8/2018 13:17

This will do a farn soon. Big profits going this way for me soon

[the canadian mounted] 07/8/2018 11:51

Good luck to all 😁

[someuwin] 07/8/2018 11:40

Yes - good time to be accumulating. imo.

[kirk 6] 07/8/2018 11:10

I've been buying and will buy more tomorrow. Got 400k shares now

[someuwin] 07/8/2018 09:57

Saw this piece in The Times a few weeks back...

Develop new antibiotics or face fines, drug firms told



It talks about forcing drug companies to develop new antibiotics or face heavy financial penalties. One obvious way for any major pharma co to comply with such rules is just to buy SUMM.

Which I'm sure will happen.

[the canadian mounted] 07/8/2018 09:32

Purchased another load this morning very confident of this company.

[kirk 6] 06/8/2018 13:49

Summit Therapeutics plc Summit Therapeutics To Present At The Canaccord Genuity Growth ConferenceSource: UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics to Present at the Canaccord Genuity Growth Conference Oxford, UK, and Cambridge, MA, US, 6 August 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the Canaccord Genuity Growth Conference on 9 August 2018 at 8:00am EDT in Boston. A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. For more information, please contact: Summit Glyn Edwards / Richard Pye (UK office) Tel: [phone] Erik Ostrowski / Michelle Avery (US office) [phone] Cairn Financial Advisers LLP (Nominated Adviser) Tel: [phone] Liam Murray / Tony Rawlinson N+1 Singer (Joint Broker) Tel: [phone] Aubrey Powell / Jen Boorer Panmure Gordon (Joint Broker) Tel: [phone] Freddy Crossley, Corporate Finance James Stearns, Corporate Broking MSL Group (US) Tel: [phone] Jon Siegal [e-mail] Consilium Strategic Communications (UK) Tel: [phone] Mary-Jane Elliott / Jessica Hodgson [e-mail] / Lindsey Neville -END- This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Summit Therapeutics plc via Globenewswire (END) Dow Jones NewswiresAugust 06, 2018 07:00 ET (11:00 GMT)Copyright (c) 2018 Dow Jones & Company, Inc.

[the canadian mounted] 05/8/2018 10:27

It takes a while for the market to catch up that’s why I’m holding until I get the price I’m happy to sell at.

[the canadian mounted] 05/8/2018 10:25

Trinko pretty obvious to develop the product to the market.

[kirk 6] 05/8/2018 08:20

Agreed £1.30-£1.35 or 100m mkp is fair value here. All the news recently hasn't had any effect but it will catch up here. Hopefully next week will close above 60p

[waterloo01] 05/8/2018 07:26

Apart from redundancy costs, cash burn should be low as they have stopped all DMD work, so was £27m at end April. They have up to $62m in Barda grant (non dilutive) toward expected $100m cost to get RDZ through it's two phase 3 trials, add on Discuva recent £10m investment that so far has identified a new target in Gonorrhoea. So for $100m essentially someone gets a funded phase 3 antibiotic for little actual outlay.

That's why this is worth at least $100m now IMO and in the opinion of recent director buys.

[trinko] 05/8/2018 02:07

and cash burn??

[the canadian mounted] 04/8/2018 18:52

Kirk6 is correct in thinking this price is achievable.current valuation of cash assets is not reflective of the company products currently in the pipeline.
One failure does not deserve a 80% drop in share price,a re rating imo will occur soon.

[trinko] 04/8/2018 16:37

Think he is a pumper, he is posting mostly in shares whit a big hit

[wildbunch] 04/8/2018 15:31

Kirk 6. what is your rationale for £1 plus value in 'only a matter of time?'

[wildbunch] 04/8/2018 15:31

Kirk 6. what is your rationale for £1 plus value in 'only a matter of time?'

[kirk 6] 03/8/2018 22:43

These are significantly undervalued without today's news. Only a matter of time till these are trading back above £1 so 100% rises will happen in the short term

[clarkey26] 03/8/2018 22:32

They released the news to Nasdaq yesterday after UK close and little reaction from Nasdaq, that's why we had 7am RNS rather than usual joint 12 noon release. This wasn't anything really that we didn't already know, more a journal publishing findings following an academic assessment, if material would have been 12 noon RNS. I was surprised by uplift and spike, not so much the retreat, essentially we do seem now we have a lot of short term value hunters, nothing wrong it that just will make it more volatile. I suspect some people bought in this morning without really knowing back story and thinking this was big new announcement.